Retatrutide (LY3437943), 99.9% Purity Peptide 20mg Not For Human Use, Lab Use Only. Must have professional license to order this item.

Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)

Amino acid length: 39
Purity: 99.9%
Method: HPLC
Molecular formula: C221H342N46O68
Molecular weight: 4731.33
CAS#: 2381089-83-2
Source: Synthetic
Form: Powder

Description: Retatrutide is the first triple agonist peptide targeting the Glucagon, GLP-1, and GIP receptors (3G), the EC50 values are 5.79 nM, 0.0643 nM, and 0.775 nM respectively [1]. 
Among its predecessors, Liraglutide (Victoza, Saxenda), Exenatide (Byetta), Semaglutide (Ozempic, Rybelsus, Wegovy), Lixisenatide (Adlyxin), Dulaglutide ( Trulicity) are GLP-1 receptor agonists, Tirzepatide (Mounjaro) is a GLP-1/GIP dual receptor co-agonist. Survodutide is a Glucagon/GLP-1 dual receptor co-agonist.
Retatrutidere is administered subcutaneously, with a half-life of 6 days, and therefore can be injected weekly [2]. After 48 weeks, Retatrutide achieved 24.2% weight loss in obese or overweight patients and produced 17% weight loss in diabetic patients, making it arguably the most powerful pipeline today. In addition, Retatrutide also achieved up to 86% reduction in liver fat in patients with NASH (non-alcoholic steatohepatitis) [2].
A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The liver fat (LF) reduction at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% (placebo)[3].
Storage: This peptide will normally be delivered in lyophilized form and stored in a freezer at or below -20 °C. For more details, please refer to the manual: 

Download the MSDS Here

Download the COA here

Download storage guide Here